Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT04115631

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions Liver Lymphoma Mantle Cell Lymphoma

Interventions Acalabrutinib Bendamustine Bendamustine Hydrochloride Cytarabine Rituximab

Updated 21 times since 2019 Last updated: Feb 27, 2026 Started: Dec 13, 2019 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Liver Lymphoma and Mantle Cell Lymphoma and is currently ongoing. ECOG-ACRIN Cancer Research Group leads this study, which shows 21 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

21 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE2
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE2
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE2

▶ Show 16 earlier versions

Oct 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE2
Jan 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2
Sep 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Jun 2023 — Jul 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE2
Sep 2021 — Sep 2022 [monthly]

Recruiting PHASE2
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Jun 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Dec 2019 — Jun 2020 [monthly]

Recruiting PHASE2
Nov 2019 — Dec 2019 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Adrian, United States , Aitkin, United States , Alton, United States , American Fork, United States , Ames, United States , Anaconda, United States , Anaheim, United States , Anchorage, United States , Ann Arbor, United States and 336 more locations